DPMI-δ-C

General Information


DRACP ID  DRACP01469

Peptide Name   DPMI-δ-C

Sequence  WYⓍNFEⓍLLR

Sequence Length  10

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic construct

Type  Synthetic peptide

Classification

  

Active ACP Cancer targeted peptides Stapled Peptides MDM2/MDMX antagonists



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  MDM2, MDMX

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01469

Helicity  Not available

Linear/Cyclic  Cyclic (Stapled)

Disulfide/Other Bond  Stapled: Ⓧ(3) and Ⓧ (7) are cross-linked by hydrocarbon stapling

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  Ⓧ(3)=(S)-2- (4'-pentenyl)alanine or (R)-2- (4'- pentenyl)alanine; Ⓧ(7)=(S)-2- (4'-pentenyl)alanine or (R)-2- (4'- pentenyl)alanine

Chiral  L



Physicochemical Information


Formula  C62H87N15O15

Absent amino acids  CDGHIKMPQSTV

Common amino acids  AL

Mass  144318

Pl  6.4

Basic residues  1

Acidic residues  1

Hydrophobic residues  6

Net charge  0

Boman Index  -974

Hydrophobicity  3

Aliphatic Index  98

Half Life 
  Mammalian: 2.8 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  6990

Absorbance 280nm  776.67

Polar residues  2

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US20120328692A1

Patent Title  Potent D-peptide antagonists of mdm2 and mdmx for anticancer therapy.

Other Iinformation  Granted Patent Family: 8s / 8ex; Family Jurisdictions: CN, DK, US, EP, ES; Legal Status: Active; Application No: 16168397; Filed:May 4, 2016; Published: Jul 17, 2019; Earliest Priority: May 7, 2015; Granted: Jul 17, 2019

Other Published ID  Not available




DRACP is developed by Dr.Zheng's team.